Last reviewed · How we verify
romiplostim plus dexamethasone
Romiplostim stimulates thrombopoietin receptors to increase platelet production, while dexamethasone provides immunosuppressive and anti-inflammatory effects to treat immune thrombocytopenia.
Romiplostim stimulates thrombopoietin receptors to increase platelet production, while dexamethasone provides immunosuppressive and anti-inflammatory effects to treat immune thrombocytopenia. Used for Immune thrombocytopenia (ITP).
At a glance
| Generic name | romiplostim plus dexamethasone |
|---|---|
| Also known as | ROM + DEX |
| Sponsor | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla |
| Drug class | Thrombopoietin receptor agonist plus corticosteroid |
| Target | Thrombopoietin receptor (TPO-R); glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Hematology/Immunology |
| Phase | Phase 3 |
Mechanism of action
Romiplostim is a thrombopoietin receptor agonist that binds to the TPO receptor on megakaryocyte progenitor cells, stimulating platelet production. Dexamethasone is a corticosteroid that suppresses immune-mediated platelet destruction. The combination targets both platelet production and immune-mediated destruction in immune thrombocytopenia (ITP).
Approved indications
- Immune thrombocytopenia (ITP)
Common side effects
- Headache
- Thrombosis
- Infection
- Hyperglycemia
- Insomnia
Key clinical trials
- Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia (PHASE3)
- Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional Trial (PHASE2)
- A Study of Romiplostim N01 as the First-line Treatment for Newly Diagnosed Adult Patients With ITP (PHASE2)
- Immune Thrombocytopenia Management in Adults (PHASE4)
- Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma (PHASE1, PHASE2)
- Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: